
News from news38.de
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top news38.de News

Europe · GermanyBioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.See the Story
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
45% Center coverage: 27 sources
German economic institutes raise growth forecasts
53% Center coverage: 15 sources